A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors
Conclusions Crenigacestat was tolerated in Japanese patients but with limited clinical activity. The recommended crenigacestat dose in Japanese patients is 50 mg TIW.Trial registration: NCT02836600 (ClinicalTrials.gov) registered on July 19, 2016.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research